Abstract
The prevalence of hypertrophic cardiomyopathy is estimated at 1:500 in the general population. Of these patients, approximately 1% develops midcavitary obstruction and subsequent apical aneurysm. We present a brief review of the literature on apical hypertrophic cardiomyopathy (HCM) using a rare case-based example. The etiology for apical aneurysm development is unclear but is thought to extend from apical fibrosis and necrosis secondary to subendocardial ischemia. The lifetime risk of cardiovascular death in patients with HCM is 2%. However, the risk may be higher in patients with apical aneurysms. Definitive therapy involves implantation of an automatic implantable cardioverter defibrillator, since medical therapy has variable success.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
